Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy

Fig. 3

Leronlimab blocks human CCR5-mediated signaling by CCL3 and CCL4 in human breast cancer cells. a MDA-MB-231-CCR5 cells were assessed for Ca+ 2 fluxes using Fluo-4 as a calcium concentration indicator. Fluorescence was measured at time points after the addition of either CCL3 (a, b) or CCL4 (c, d) in the presence of either CCR5 inhibitors (leronlimab, vicriviroc) or control IgG. b, d Quantitation of the time course of Ca+ 2-induced fluorescence was obtained from living cell imaging (a, c

Back to article page